About Sequestosome-1
Sequestosome-1 (SQSTM1) is a protein
from Homo sapiens identified by UniProt accession
Q13501, 440 residues long.
MolForge cross-references it against 0 known binders and
624 disease associations.
Target properties
| Protein name | Sequestosome-1 |
| UniProt accession | Q13501 |
| Gene | SQSTM1 |
| Organism | Homo sapiens |
| Length | 440 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (624)
Diseases linked to this target (Open Targets).
- osteitis deformans · score 0.79
- neurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onset · score 0.71
- amyotrophic lateral sclerosis · score 0.66
- behavioral variant of frontotemporal dementia · score 0.66
- frontotemporal dementia with motor neuron disease · score 0.66
- Distal myopathy, Nonaka type · score 0.61
- frontotemporal dementia and/or amyotrophic lateral sclerosis 1 · score 0.55
- cancer · score 0.49
- osteosarcoma · score 0.49
- neurodegenerative disease · score 0.45
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q13501-F1 | alphafold | PREDICTED | 67.25 | — |
Amino-acid sequence (440 residues)
MASLTVKAYL LGKEDAAREI RRFSFCCSPE PEAEAEAAAG PGPCERLLSR VAALFPALRP GGFQAHYRDE DGDLVAFSSD EELTMAMSYV KDDIFRIYIK EKKECRRDHR PPCAQEAPRN MVHPNVICDG CNGPVVGTRY KCSVCPDYDL CSVCEGKGLH RGHTKLAFPS PFGHLSEGFS HSRWLRKVKH GHFGWPGWEM GPPGNWSPRP PRAGEARPGP TAESASGPSE DPSVNFLKNV GESVAAALSP LGIEVDIDVE HGGKRSRLTP VSPESSSTEE KSSSQPSSCC SDPSKPGGNV EGATQSLAEQ MRKIALESEG RPEEQMESDN CSGGDDDWTH LSSKEVDPST GELQSLQMPE SEGPSSLDPS QEGPTGLKEA ALYPHLPPEA DPRLIESLSQ MLSMGFSDEG GWLTRLLQTK NYDIGAALDT IQYSKHPPPL
Explore Sequestosome-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets